- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02478905
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)
TransFLUas: Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting: A Prospective Study Over Two Consecutive Influenza Seasons
Study Overview
Detailed Description
The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about whether asymptomatic subjects are able to transmit influenza is of major importance. If they do transmit influenza, vaccination of patients and healthcare workers (HCW) before start of the influenza season, the permanent use of masks by HCW during influenza season, and quarantine for previously exposed inpatients may be the only available measures to reduce the number of influenza transmission events from asymptomatic subjects in acute care hospitals.
The investigators' key aim is therefore to define whether exposure to asymptomatic subjects with influenza infection constitutes a risk for influenza transmission in an acute care hospital setting through active, prospective surveillance.
The investigators' secondary aims are to describe the prevalence of community-acquired symptomatic and asymptomatic influenza upon hospital admission and the incidence of asymptomatic and symptomatic nosocomial influenza among inpatients; to assess transmission dynamics of symptomatic influenza infection in acute care; and to study the incidence of asymptomatic and symptomatic influenza, absenteeism (i.e. being absent from work due to influenza), presenteeism (i.e. being present at work despite influenza infection) associated with influenza, and compliance with infection control recommendations to prevent spread of influenza in acute care HCW.
The investigators plan to enroll 1,260 inpatients and 180 HCW from medical wards at the University Hospital Zurich in a prospective study over two consecutive influenza seasons in order to detect at least one transmission event from an asymptomatic individual shedding influenza virus. Flocked mid-turbinate nasal swabs will be collected daily from consenting inpatients starting from day of admission until two days after discharge and from HCW over the influenza (winter) season and analyzed for influenza A and B using polymerase chain reaction. Simultaneously, signs and symptoms of influenza infection (including cough, sore throat, fever >37.8°C, nasal congestion, weakness, headache, loss of appetite or myalgia) as well as contact patterns between inpatients and HCW will be recorded. Reconstruction of influenza transmission chains will be based on phylogenetic analyses derived from next-generation sequence data and epidemiological contact tracing.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland
- University Hospital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 or more years of age;
- Available for follow-up during the study period;
- If a HCW: employed full- or part-time (≥50% full-time equivalent);
- Understand the study, agree to its provisions, and give written informed consent (as documented by signature).
Exclusion Criteria:
- If a HCW: planning to spend more than two consecutive weeks outside of Switzerland during the winter study period (November 1st to April 31st);
- If a HCW: planning to take leave from work for more than two consecutive weeks during the winter study period (e.g. maternity or medical leave);
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject;
- Known or suspected non-compliance.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
surveillance cohort
Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary attack rate of asymptomatic or presymptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting
Time Frame: up to 6 months
|
diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact.
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting
Time Frame: up to 6 months
|
Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting: as diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact. Transmissions will be considered 'proven' if confirmed by phylogenetic analyses. Specifically, we expect that whole-genome sequence analysis will demonstrate identical or almost identical influenza strains within transmission chains. Transmissions will be considered 'probable' if there is epidemiological evidence of face-to-face contact and identical strains have been identified in PCR but whole-genome sequencing was technically unsuccessful; |
up to 6 months
|
|
Proportion of asymptomatic and symptomatic inpatients with influenza infection upon hospital admission: as diagnosed by influenza polymerase chain reaction (PCR) from flocked mid-turbinate nasal swabs collected upon hospital admission
Time Frame: up to 6 months
|
diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected upon hospital admission
|
up to 6 months
|
|
Incidence of asymptomatic (A5) and symptomatic (A6) nosocomial influenza in hospital inpatients, defined as the number of emerging influenza infections >72 hours after hospital admissions per 100 patient-days
Time Frame: up to 6 months
|
diagnosed by PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season
|
up to 6 months
|
|
Incidence of asymptomatic (A7) and symptomatic (A8) influenza in acute care hospital workers defined as the number of influenza infections per 100 HCW per influenza season
Time Frame: up to 6 months
|
diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season collected three times per week over the influenza season
|
up to 6 months
|
|
Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection
Time Frame: up to 6 months
|
Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection
|
up to 6 months
|
|
Influenza-attributable mortality in inpatients, expressed as infection-fatality rate, i.e. number of deaths among those infected
Time Frame: up to 6 months
|
number of deaths among those infected
|
up to 6 months
|
|
Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW
Time Frame: up to 6 months
|
Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW;
|
up to 6 months
|
|
Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection
Time Frame: up to 6 months
|
Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection;
|
up to 6 months
|
|
Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations
Time Frame: up to 6 months
|
Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations;
|
up to 6 months
|
|
Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding
Time Frame: up to 6 months
|
Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding;
|
up to 6 months
|
|
Association between viral load and asymptomatic or symptomatic transmission based on quantification of viral shedding according to cycle threshold (Ct) values from PCR
Time Frame: up to 6 months
|
defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e.
exceeds background level).
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stefan Kuster, MD, Division of Infectious Diseases and Hospital Epidemiology
Publications and helpful links
General Publications
- Kuster SP, Boni J, Kouyos RD, Huber M, Schmutz S, Shah C, Bischoff-Ferrari HA, Distler O, Battegay E, Giovanoli P, Guckenberger M, Kohler M, Muller R, Petry H, Ruschitzka F, McGeer A, Coleman BL, Sax H, Weber R, Trkola A. Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infect Control Hosp Epidemiol. 2021 Mar;42(3):268-273. doi: 10.1017/ice.2020.444. Epub 2020 Nov 26.
- Schwarz H, Boni J, Kouyos RD, Turk T, Battegay E, Kohler M, Muller R, Petry H, Sax H, Weber R, McGeer A, Trkola A, Kuster SP. The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients. BMC Infect Dis. 2019 May 21;19(1):446. doi: 10.1186/s12879-019-4057-5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH-Nr. 2015-0228
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Influenza
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
AVIR Green Hills Biotechnology AGCompletedSeasonal Human InfluenzaAustria
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Institute of Medical Biology, Chinese Academy of...Guangxi Zhuang Autonomous Region Center for Disease Prevention and ControlNot yet recruitingInfluenza, Human | Influenza Viral Infections | Influenza B | Influenza, Human Prevention | Influenza aChina
-
NovartisNovartis VaccinesCompleted
-
Butantan InstituteFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Centers for Disease Control and PreventionUniversidad del Valle, Guatemala; Hospital Nacional San Juan de Dios de Santa... and other collaboratorsTerminatedInfluenza | Human InfluenzaPanama, El Salvador
-
Novartis VaccinesCompletedHuman InfluenzaBelgium
-
Hualan Biological Engineering, Inc.Completed
-
Meso Scale Diagnostics, LLC.Centers for Disease Control and PreventionTerminated
Clinical Trials on Influenza
-
PfizerCompletedInfluenza, HumanUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic Malignancy | Hematopoietic Stem Cell TransplantUnited States
-
Aramis Biotechnologies Inc.Recruiting
-
Novartis VaccinesCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Nanogen, Inc.Suspended
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus InfectionUnited States